Safety, PK and PD Study of ABX464 in Untreated HIV Patients
Completed
Abivax S.A.
Phase 2
ABX464 is a first in class that showed efficacy as an anti-HIV therapy. The present study is
intended to assess the safety, the tolerability, and pharmacokinetic parameters and to
evaluate the effect on viral load of repeated oral administrations of ABX464 in patients
infected by HIV, not previously treated for their HIV.
Two types of design are intended in this protocol: dosing every 3 days or dosing every day.
The goal is to determine the best dosing regimen to reduce viral load and minimize adverse
events.
ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor Treatment
Completed
Abivax S.A.
Phase 2
This study is a placebo-controlled study aimed at assessing the safety of ABX464 administered
at 50 mg and 150 mg o.d. versus placebo in HIV infected patients who are treated with
darunavir + ritonavir (DRV/RTV) or darunavir + cobicistat (DRV/COBI).
A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive Adults
Completed
FLS-RS
Phase 1/Phase 2
The purpose of the ABX464-005 study is to characterize the systemic and mucosal immunological
sequelae associated with exposure to ABX464 and to explore selected immunological endpoints,
compartmental pharmacokinetics, and pharmacodynamics.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
